Related Experiment Videos
Current perspectives on the use of circulatory assist devices
Insights
Circulatory assist devices (CADs) offer hope for heart failure patients awaiting transplants or recovery. Successful use demands careful patient selection, team readiness, and understanding device limitations for optimal outcomes.
Area of Science:
- Cardiovascular Medicine
- Biomedical Engineering
Background:
- Heart failure remains a significant health challenge, necessitating advanced therapeutic options.
- Circulatory assist devices (CADs) represent a critical technological advancement in managing end-stage heart disease.
Purpose of the Study:
- To provide an overview of current circulatory assist devices (CADs).
- To discuss the optimal use, limitations, and management of CADs.
- To highlight the role of regulatory bodies in CAD development.
Main Methods:
- Review of available circulatory assist devices (CADs).
- Discussion of key factors for successful CAD application: team readiness, patient selection, device limitations, patient management, and complication avoidance.
- Examination of the current status of CADs in clinical trials and regulatory approval processes.
Main Results:
- Various CADs are available, each with specific applications and limitations.
- Successful implementation hinges on comprehensive management strategies and understanding device constraints.
- Many devices are undergoing Food and Drug Administration (FDA) review, indicating active development.
Conclusions:
- Effective use of CADs requires a multidisciplinary approach and thorough patient assessment.
- Ongoing technological advancements, including totally implantable systems, are expanding treatment possibilities.
- The ultimate aim is to improve quality of life for heart failure patients through cost-effective, implantable device solutions.
Abstract:
An overview of currently available circulatory assist devices (CADs) is presented with discussion of each system's optimal use and limitations. Successful application of CAD technology for bridge to transplant or pending recovery of the natural heart requires understanding issues involving team readiness, patient selection, device limitations, patient management, and complications. Currently, many of these devices are in clinical trials with the Food and Drug Administration (FDA). The FDA and the National Institutes of Health play major roles in the ongoing development of this technology. In the near future the learning curve continues as totally implantable systems are used. The ultimate goal is to maintain patients with heart failure on implantable devices with a good quality of life at a reasonable cost.